Effect of chemotherapy on urinary volatile biomarkers for lung cancer by HS‐SPME‐GC‐MS and chemometrics

Abstract

AbstractBackgroundVolatile organic compounds (VOCs) have been studied as possible biomarkers in several diseases, including lung cancer. Early detection of cancer can improve long‐term survival rates and the quality of life, so the study of VOCs in exhaled breath and urine has been increasing in recent years. This study aimed to assess the urinary VOCs that are modified after chemotherapy to identify those with the potential to be lung cancer biomarkers that can be monitored during treatment.MethodsThree urine samples from 10 men with stage IV lung adenocarcinoma were collected, as well as urine samples from 14 men with other types of cancer (control group). All samples were analyzed by headspace‐solid phase microextraction gas chromatography coupled with mass spectrometry.ResultsA total of 21 urinary VOCs were found with different levels after the administration of chemotherapy, with 2‐pentanone being one of those that significantly decreased. Furthermore, 2‐pentanone and 3‐hydroxy‐2,4,4‐trimethylpentyl‐2‐methylpropanoate showed statistically significant differences with the control group.ConclusionsChemotherapy administered to patients with advanced lung adenocarcinoma modified the volatile profile of urine. 2‐Pentanone, a final product of the increased rate of fatty acid oxidation and protein hypermetabolism, significantly decreased after chemotherapy. Therefore, monitoring its urinary excretion could be very useful since its decrease over time could indicate an adequate response to chemotherapy and arrest of cancer development. Another VOC that could be a potential lung cancer biomarker is 3 hydroxy‐2,4,4‐trimethylpentyl‐2‐methylpropanoate, whose origin may be due to inhibition of the propanoic acid metabolic pathway or increased aldehyde dehydrogenase activity.